Cambridge Cognition Holdings PLC Grant of Options (3005O)
November 04 2016 - 2:00AM
UK Regulatory
TIDMCOG
RNS Number : 3005O
Cambridge Cognition Holdings PLC
04 November 2016
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Grant of Options
The neuroscience company Cambridge Cognition Holdings PLC
(Cambridge, UK - LSE: COG), which develops and markets near patient
technologies to facilitate the development of treatments for
neurological disorders, announces that on 3 November 2016, the
Company granted options ("Options") over a total of 1,150,000
ordinary shares of 1 pence each in the capital of the Company
("Ordinary Shares") pursuant to the Company's EMI option scheme and
the Company's unapproved option scheme.
Of these Options:
- 550,000 were granted to Steven Powell, Chief Executive Officer of the Company;
- 150,000 were granted to Nick Walters, Chief Financial Officer of the Company;
- 175,000 were granted to other Persons Discharging Managerial
Responsibilities ("PDMRs") on behalf of the Company; and
- 275,000 were granted to other employees of the Company.
Name Position Total Total Percentage Number Percentage
number number of the of Ordinary of the
of new of Options Company's Shares Company's
Options now current currently current
granted held share held share
capital capital
now held held
under
Option
-------------- ----------------- --------- ------------ ----------- ------------- -----------
Steven Chief Executive
Powell Officer 550,000 675,000 3.3% 70,541 0.3%
-------------- ----------------- --------- ------------ ----------- ------------- -----------
Chief Financial
Nick Walters Officer 150,000 300,000 1.5% 186,937 0.9%
-------------- ----------------- --------- ------------ ----------- ------------- -----------
The Options are exercisable at a price of 1 pence per Ordinary
Share from three years following the date of award until the tenth
anniversary of the date of award, subject to satisfying the
following performance criteria:
- 55% of the Options granted will vest if the average closing
mid-market price of an Ordinary Share for the final 10 trading days
of 2018 is greater than 140 pence per Ordinary Share. A pro rata
sliding scale will apply if the average closing mid-market price of
an Ordinary Share for the final 10 trading days of 2018 is between
100 pence and 140 pence per Ordinary Share; and
- 45% of the Options granted will vest if the cumulative revenue
of the Company reported in the audited accounts for the three
financial years ended 31 December 2018 exceeds GBP23m.
Following the grant of Options, the total number of Options
outstanding over unissued Ordinary Shares is 2,961,208 Ordinary
Shares, representing approximately 14.5% of the Company's issued
share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1. Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Names Steven Powell - Chief Executive
Officer
Nick Walters - Chief Financial
Officer
Jennifer Barnett - Chief Scientific
Officer
Ricky Dolphin - Technical
& Operations Director
--- ------------------------- -------------------------------------
2. Reason for the Notification
--- ----------------------------------------------------------------
a) Position/status See 1(a) above for positions
- all classified as PDMRs
of the Company
--- ------------------------- -------------------------------------
b) Initial notification/ Initial Notification
Amendment
--- ------------------------- -------------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ----------------------------------------------------------------
a) Name Cambridge Cognition Holdings
Plc
--- ------------------------- -------------------------------------
b) LEI n/a
--- ------------------------- -------------------------------------
4. Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------------------
a) Description of In each case, the grant of
the Financial Options over Ordinary Shares
instrument, type on 3 November 2016
of instrument
---
Identification GB00B8DV9647
code
--- ------------------------- -------------------------------------
b) Nature of the Grant of Options over Ordinary
transaction Shares
--- ------------------------- -------------------------------------
c) Price(s) and Price: n/a
volume(s) Volumes:
Steven Powell - 550,000 Options
Nick Walters - 150,000 Options
Jennifer Barnett - 150,000
Options
Ricky Dolphin - 25,000 Options
--- ------------------------- -------------------------------------
d) Aggregated information: n/a
* Aggregated volume
* Price
--- ------------------------- -------------------------------------
e) Date of the transaction 3 November 2016
--- ------------------------- -------------------------------------
f) Place of the Outside a trading venue
transaction
--- ------------------------- -------------------------------------
Enquiries
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Product press@camcog.com
Marketing and Communications
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane (Corporate Broking)
Hybridan LLP (Joint Broker) Tel: 020 3764
2341
Claire Noyce (Corporate Broking)
Notes to editors
About Cambridge Cognition
Cambridge Cognition is an international neuroscience company
which develops and markets near patient cognitive assessment
products to improve the understanding, diagnosis and treatment of
neurological and psychiatric disorders.
For over 30 years the company's patented technology has advanced
the assessment of cognition to accelerate the development of safe
and effective treatments, improve patient outcomes and measure
cognitive health throughout life.
Partners include the world's leading biotechnology and
pharmaceutical companies, academic institutions and public-private
healthcare providers.
www.cambridgecognition.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHQXLFBQFFEFBK
(END) Dow Jones Newswires
November 04, 2016 03:00 ET (07:00 GMT)